Importantly, it was shown that neoadjuvant therapy leads to the upregulation of Lcn-2 in human breast tumors, highlighting the importance of targeting Lcn-2 as an additional therapeutic approach [108]. This evidence concerns the gene LCN2 and breast neoplasm.